RIPK3 and prostate carcinoma: Contrastingly, Wang et al. [174] showed that upregulation of RIPK3 expression reduces prostate cancer cells proliferation and tumorigenicity both in vitro and in vivo via phosphorylating MLKL, which was reversed by treatment of the MLKL inhibitor, suggesting that necroptosis induces cell death in prostate cancer cells.